Neutralizing activity to SARS-CoV-2 in 1.2 to 10.0 month convalescent plasma samples of COVID-19: A transversal surrogate in vitro study performed in Quito-EcuadorCOVID-19의 1.2~10.0개월 회복기 혈장 샘플에서 SARS-CoV-2에 대한 중화 활성: 키토-에콰도르에서 수행된 횡단 대리 시험관내 연구Article Published on 2022-09-012022-09-11 Journal: Journal of medical virology [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술, [키워드] absence acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 addition analyzed binding domain BSL2 facility BSL3 caused convalescence Convalescent patients convalescent plasma convalescent sera coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 determine diagnostic methods Ecuador glycoprotein IgG IgM Immunoglobulin Immunoglobulin G immunoglobulin M in some in vitro study Infection NAb NAbs neutralization test Neutralizing Neutralizing activity Neutralizing antibodies neutralizing antibody performed plasma plasma. positive presence or absence Quito remained reported respiratory SARS-CoV-2 Seroconversion severe acute respiratory syndrome Coronavirus surrogate Test the SARS-CoV-2 Viral viral spike virus Wuhan Wuhan, China [DOI] 10.1002/jmv.27866 PMC 바로가기 [Article Type] Article
SARS-CoV-2 variants of concern: spike protein mutational analysis and epitope for broad neutralization우려되는 SARS-CoV-2 변이체: 스파이크 단백질 돌연변이 분석 및 광범위한 중화를 위한 에피토프Article Published on 2022-08-182022-09-11 Journal: Nature Communications [Category] SARS, 변종, 진단, 치료기술, [키워드] Analysis antibody Antibody neutralization antigenic binding circulating variants Comparative analysis consequence convalescent sera cryo-EM Effect ENhance epitope exhibit functional Gamma highlight identify mutated Mutation N-terminal domain neutralization neutralize NTD omicron RBD SARS-CoV-2 spike SARS-CoV-2 spike mutations SARS-CoV-2 variant SARS-CoV-2 variants shown spike glycoprotein spike glycoproteins Spike protein structural rearrangements unique variant variant spike [DOI] 10.1038/s41467-022-32262-8 PMC 바로가기 [Article Type] Article
Omicron mutations enhance infectivity and reduce antibody neutralization of SARS-CoV-2 virus-like particlesOmicron 돌연변이는 SARS-CoV-2 바이러스 유사 입자의 감염성을 높이고 항체 중화를 감소시킵니다.Article Published on 2022-08-022022-09-11 Journal: Proceedings of the National Academy of Sciences of [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료기술, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 addition Antibody neutralization Antisera assembly B.1 B.1 lineage B.1.1 bebtelovimab Casirivimab Cell cell entry change convalescent sera coronavirus COVID-19 Delta detectable detrimental dose Effect Efficacy Efficiency eight eight subject elicited ENhance examined Imdevimab individual Johnson & Johnson Johnson & Johnson luciferase Moderna monoclonal antibodies monoclonal antibody Mutation N proteins neutralization neutralization activity neutralization titer Neutralizing antibodies neutralizing antibody omicron Omicron variant Patient Pfizer Pfizer/BioNTech Prevent property reduce reduced respiratory resulting robust SARS-CoV-2 SARS-CoV-2 variant sequence sera severe acute respiratory syndrome Coronavirus Spike protein Spread structural protein structural proteins subjects survivor Vaccine Vaccines variant variants Viral viral infectivity Virus-like particle virus-like particles virus-like particles. VLP VLPs [DOI] 10.1073/pnas.2200592119 PMC 바로가기 [Article Type] Article
Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies회복기 및 백신 혈청 및 단일 클론 항체에 의한 SARS-CoV-2 오미크론 하위 변이체 BA.1 및 BA.2의 제한된 중화Article Published on 2022-08-012022-09-11 Journal: EBioMedicine [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] ACE2 addition antibody BA.1 BA.2 BNT162b2 booster booster dose booster vaccination breakthrough infections Casirivimab Cell Complete convalescent convalescent sera Delta dominant dose education Efficacy elicited exhibited expressing Frankfurt Imdevimab Immunity in vitro study individual infection with SARS-CoV-2 Limited majority median monoclonal antibodies monoclonal antibody monoclonal antibody therapy Mutation neutralisation neutralise neutralising neutralizing capacity omicron Omicron variants reduced Region SARS-CoV-2 sera serum Sotrovimab specific resistance Spike protein supported tested the SARS-CoV-2 the spike protein therapy TMPRSS2 university vaccination Vaccine Vaccines variants variants of SARS-CoV-2 waning immunity Waning Immunity. [DOI] 10.1016/j.ebiom.2022.104158 PMC 바로가기 [Article Type] Article
Pre-Omicron Vaccine Breakthrough Infection Induces Superior Cross-Neutralization against SARS-CoV-2 Omicron BA.1 Compared to Infection AlonePre-Omicron 백신의 획기적인 감염은 단독 감염에 비해 SARS-CoV-2 Omicron BA.1에 대해 우수한 교차 중화를 유도합니다Article Published on 2022-07-122022-09-11 Journal: International Journal of Molecular Sciences [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료법, [키워드] antibody antibody levels Antibody Response Antibody responses B.1 boost Breakthrough infection comparable convalescent convalescent sera convalescent serum correlated COVID-19 patient cross-neutralization cross-neutralizing antibodies cross-neutralizing antibody Delta disease elicited evade form Gamma had no higher affinity highlight Immunity individuals induce infecting Infection Live virus Mild moderate disease N-terminal domain neutralization neutralize Neutralizing Neutralizing activity Neutralizing antibodies neutralizing antibody neutralizing capacity NTD nucleocapsid omicron Omicron BA.1 Patient patients with moderate Protein Proteins raise RBD Receptor-binding domain remained retained SARS-CoV-2 SARS-CoV-2 variants sera spike Spike protein Spike proteins strain Strains Superior the disease the RBD the receptor-binding domain the Spike the spike protein Transmissibility vaccination Vaccine Variability variant variants variants of concern variants of concern (VOCs). virus-induced antibodies VoC VOCs [DOI] 10.3390/ijms23147675 PMC 바로가기 [Article Type] Article
Physicochemical effect of the N501Y, E484K/Q, K417N/T, L452R and T478K mutations on the SARS-CoV-2 spike protein RBD and its influence on agent fitness and on attributes developed by emerging variants of concernSARS-CoV-2 스파이크 단백질 RBD에 대한 N501Y, E484K/Q, K417N/T, L452R 및 T478K 돌연변이의 물리화학적 효과와 에이전트 적합성 및 우려되는 신흥 변이체에 의해 개발된 속성에 대한 영향Review Published on 2022-07-012022-09-11 Journal: Virology [Category] COVID19(2023년), SARS, 변종, [키워드] addition agent Alter attribute attributes binding caused changes in complex component convalescent sera Effect evade Evolution favor greater immune pressure immunodominant immunogenic induce inducer infection control infection process involved K417N L452R manuscript Mutation mutations N501Y occur Occurrence physicochemical Physicochemical effects Protective antibody RBD Receptor binding domain regions SARS-CoV-2 selective Spike protein spike protein RBD T478K target cells the RBD the SARS-CoV-2 the spike protein therapy Transmissibility turn Vaccine variant Variant of concern. variants of concern Viral transmission virulence virus virus expansion virus genome VoC VOCs [DOI] 10.1016/j.virol.2022.05.003 PMC 바로가기 [Article Type] Review
Absence of neutralizing antibodies against the Omicron SARS-CoV-2 variant in convalescent sera from individuals infected with the ancestral SARS-CoV-2 virus or its Gamma variantArticle Published on 2022-06-162022-11-15 Journal: Clinics [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] antibody convalescent sera dominant effective evaluate Gamma Gamma variant Hospitalization in vitro individual individuals Infection Mild moderate Neutralizing antibodies neutralizing antibody Neutralizing antibody response omicron Omicron variant pandemic positive Protective protective antibodies SARS-CoV-2 SARS-CoV-2 vaccine SARS-CoV-2 variant SARS-CoV-2 virus SARS-CoV-2. sera serum strain Symptom the SARS-CoV-2 variant variants [DOI] 10.1016/j.clinsp.2022.100068 PMC 바로가기
Immunogenicity of convalescent and vaccinated sera against clinical isolates of ancestral SARS-CoV-2, Beta, Delta, and Omicron variants조상 SARS-CoV-2, 베타, 델타 및 오미크론 변이체의 임상 분리주에 대한 회복기 및 백신 접종 혈청의 면역원성Article Published on 2022-06-102022-09-11 Journal: Med (New York, N.Y.) [Category] COVID19(2023년), MERS, SARS, 변종, 임상, 진단, [키워드] antibody Antibody titers Beta booster vaccination Canada CL3 clinical isolates convalescent convalescent individual convalescent individuals convalescent sera coronavirus coronavirus disease COVID-19 Delta delta variant demonstrated dose foundation Government immunogenicity individual induce initiative Innovation isolate long-term Major microneutralization Ministry of Agriculture Moderna multiple mutation multiple mutations neutralization Neutralizing Neutralizing activity Neutralizing antibodies neutralizing antibody Neutralizing antibody titer omicron Omicron variant Pfizer raising receive recipient reduced Research SARS-CoV-2 Science sera significantly higher Spike protein the spike protein vaccinated individual vaccinated individuals Vaccine variant variants variants of concern variants of concern. VIDO virus VoC VOCs [DOI] 10.1016/j.medj.2022.04.002 PMC 바로가기 [Article Type] Article
Three SARS-CoV-2 antibodies provide broad and synergistic neutralization against variants of concern, including Omicron3개의 SARS-CoV-2 항체는 Omicron을 포함한 관심 변이체에 대해 광범위하고 상승적인 중화를 제공합니다.Article Published on 2022-05-242022-09-11 Journal: Cell Reports [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Analysis antibody antibody cocktail Beta convalescent patient convalescent sera coronavirus Coronaviruses COVID-19 CP: Immunology Critical determinant hamsters highlighting immunology Infection inhibitory concentration Interaction maintain NAb NAbs nanomolar affinity neutralization Neutralizing antibodies neutralizing antibodies. neutralizing antibody omicron Omicron variant provide RBDs receptor-binding domains respiratory resulting reveal SARS-CoV SARS-CoV-2 SARS-CoV-2 antibody severe acute respiratory syndrome Coronavirus spike Structural analysis synergistic the receptor-binding domain therapeutic Vaccine Vaccines variant variants of concern VOCs wild-type [DOI] 10.1016/j.celrep.2022.110862 PMC 바로가기 [Article Type] Article
Humoral, Cellular and Cytokine Immune Responses Against SARS-CoV-2 Variants in COVID-19 Convalescent and Confirmed Patients With Different Disease Severities다양한 질병 중증도를 가진 COVID-19 회복기 및 확인된 환자의 SARS-CoV-2 변이체에 대한 체액, 세포 및 사이토카인 면역 반응Article Published on 2022-05-172022-09-11 Journal: Frontiers in Cellular and Infection Microbiology [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료기술, [키워드] ADE Against Alpha alpha and delta variants Alpha variant Anti-RBD IgG cellular Cellular immune response cellular immunity chemokine chemokines Confirmed convalescent convalescent sera correlation COVID-19 Cytokines delta variant Delta variants disease disease severity ELISA ELISPOT evaluate exhibited fold greater humoral Humoral and cellular immune responses humoral immune response Humoral immunity IgG IL-6 immune immune response immune responses Immunity immunoassays individual Inflammatory mediators inflammatory mediators. IP-10 MCP-1 mediators multiplex neutralization potency Neutralizing activity Omicron variant Omicron variants Patient patients performed pseudovirus pseudovirus infection quantified Raji cells RBD-specific IgG response risk SARS-CoV-1 SARS-CoV-2 SARS-CoV-2 pseudovirus infection SARS-CoV-2 variant SARS-CoV-2 variants serum severe disease Significant significantly specific antibodies spike-specific antibodies Spike-specific antibody T cell T cells variant virus was measured [DOI] 10.3389/fcimb.2022.862656 PMC 바로가기 [Article Type] Article